Literature DB >> 23801742

Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.

David Paling1, Bhavana S Solanky, Frank Riemer, Daniel J Tozer, Claudia A M Wheeler-Kingshott, Raju Kapoor, Xavier Golay, David H Miller.   

Abstract

Neuroaxonal loss is a major substrate of irreversible disability in multiple sclerosis, however, its cause is not understood. In multiple sclerosis there may be intracellular sodium accumulation due to neuroaxonal metabolic dysfunction, and increased extracellular sodium due to expansion of the extracellular space secondary to neuroaxonal loss. Sodium magnetic resonance imaging measures total sodium concentration in the brain, and could investigate this neuroaxonal dysfunction and loss in vivo. Sodium magnetic resonance imaging has been examined in small cohorts with relapsing-remitting multiple sclerosis, but has not been investigated in patients with a progressive course and high levels of disability. We performed sodium magnetic resonance imaging in 27 healthy control subjects, 27 patients with relapsing-remitting, 23 with secondary-progressive and 20 with primary-progressive multiple sclerosis. Cortical sodium concentrations were significantly higher in all subgroups of multiple sclerosis compared with controls, and deep grey and normal appearing white matter sodium concentrations were higher in primary and secondary-progressive multiple sclerosis. Sodium concentrations were higher in secondary-progressive compared with relapsing-remitting multiple sclerosis in cortical grey matter (41.3 ± 4.2 mM versus 38.5 ± 2.8 mM, P = 0.008), normal appearing white matter (36.1 ± 3.5 mM versus 33.6 ± 2.5 mM, P = 0.018) and deep grey matter (38.1 ± 3.1 mM versus 35.7 ± 2.4 mM, P = 0.02). Higher sodium concentrations were seen in T₁ isointense (44.6 ± 7.2 mM) and T1 hypointense lesions (46.8 ± 8.3 mM) compared with normal appearing white matter (34.9 ± 3.3 mM, P < 0.001 for both comparisons). Higher sodium concentration was observed in T₁ hypointense lesions in secondary-progressive (49.0 ± 7.0 mM) and primary-progressive (49.3 ± 8.0 mM) compared with relapsing-remitting multiple sclerosis (43.0 ± 8.5 mM, P = 0.029 for both comparisons). Independent association was seen of deep grey matter sodium concentration with expanded disability status score (coefficient = 0.24, P = 0.003) and timed 25 ft walk speed (coefficient = -0.24, P = 0.01), and of T1 lesion sodium concentration with the z-scores of the nine hole peg test (coefficient = -0.12, P < 0.001) and paced auditory serial addition test (coefficient = -0.081, P < 0.001). Sodium concentration is increased within lesions, normal appearing white matter and cortical and deep grey matter in multiple sclerosis, with higher concentrations seen in secondary-progressive multiple sclerosis and in patients with greater disability. Increased total sodium concentration is likely to reflect neuroaxonal pathophysiology leading to clinical progression and increased disability.

Entities:  

Keywords:  MRI; Na+ channel; disability; disease progression; multiple sclerosis

Mesh:

Substances:

Year:  2013        PMID: 23801742     DOI: 10.1093/brain/awt149

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  44 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Dietary Salt Exacerbates Experimental Colitis.

Authors:  Alan L Tubbs; Bo Liu; Troy D Rogers; R Balfour Sartor; Edward A Miao
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

Review 3.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

4.  Tissue sodium concentration and sodium T1 mapping of the human brain at 3 T using a Variable Flip Angle method.

Authors:  Arthur Coste; Fawzi Boumezbeur; Alexandre Vignaud; Guillaume Madelin; Kathrin Reetz; Denis Le Bihan; Cécile Rabrait-Lerman; Sandro Romanzetti
Journal:  Magn Reson Imaging       Date:  2019-01-26       Impact factor: 2.546

5.  Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.

Authors:  Wallace J Brownlee; Bhavana Solanky; Ferran Prados; Marios Yiannakas; Patricia Da Mota; Frank Riemer; Manuel Jorge Cardoso; Sebastian Ourselin; Xavier Golay; Claudia Gandini Wheeler-Kingshott; Olga Ciccarelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-04-04       Impact factor: 10.154

Review 6.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

Review 7.  Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis.

Authors:  Matilde Inglese; Lazar Fleysher; Niels Oesingmann; Maria Petracca
Journal:  Expert Rev Neurother       Date:  2018-01-30       Impact factor: 4.618

Review 8.  Quantitative sodium MR imaging: A review of its evolving role in medicine.

Authors:  Keith R Thulborn
Journal:  Neuroimage       Date:  2016-11-24       Impact factor: 6.556

9.  High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways.

Authors:  Ze Xiu Xiao; Xiaojiang Hu; Ximei Zhang; Zhigang Chen; Julie Wang; Ke Jin; Feng Lin Cao; Baoqing Sun; Joseph A Bellanti; Nancy Olsen; Song Guo Zheng
Journal:  Signal Transduct Target Ther       Date:  2020-04-10

10.  Exacerbation of autoimmune neuroinflammation by dietary sodium is genetically controlled and sex specific.

Authors:  Dimitry N Krementsov; Laure K Case; William F Hickey; Cory Teuscher
Journal:  FASEB J       Date:  2015-04-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.